Exact Mass: 494.3508246
Exact Mass Matches: 494.3508246
Found 325 metabolites which its exact mass value is equals to given mass value 494.3508246,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Makisteron A
Makisterone A is a steroid. Makisterone A is a natural product found in Rhodnius prolixus, Dysdercus cingulatus, and other organisms with data available.
28-Homobrassinolide
28-Homobrassinolide is found in brassicas. 28-Homobrassinolide is a constituent of chinese cabbage (Brassica rapa ssp. pekinensis) Constituent of chinese cabbage (Brassica rapa sspecies pekinensis). 28-Homobrassinolide is found in brassicas.
1-docosanoyl-glycero-3-phosphate
1-docosanoyl-glycero-3-phosphate is classified as a member of the 1-acylglycerol-3-phosphates. 1-acylglycerol-3-phosphates are lysophosphatidic acids where the glycerol is esterified with a fatty acid at O-1 position. 1-docosanoyl-glycero-3-phosphate is considered to be practically insoluble (in water) and acidic. 1-docosanoyl-glycero-3-phosphate is a glycerophosphate lipid molecule
LysoPA(22:0/0:0)
LysoPA(22:0/0:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. LysoPA(22:0/0:0), in particular, consists of one chain of behenic acid at the C-1 position. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes.
LysoPA(i-22:0/0:0)
LysoPA(i-22:0/0:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. LysoPA(i-22:0/0:0), in particular, consists of one chain of isodocosanoic acid at the C-1 position. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes.
PA(8:0/13:0)
PA(8:0/13:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(8:0/13:0), in particular, consists of one chain of caprylic acid at the C-1 position and one chain of tridecylic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(8:0/a-13:0)
PA(8:0/a-13:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(8:0/a-13:0), in particular, consists of one chain of caprylic acid at the C-1 position and one chain of anteisotridecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(8:0/i-13:0)
PA(8:0/i-13:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(8:0/i-13:0), in particular, consists of one chain of caprylic acid at the C-1 position and one chain of isotridecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
milbemycin beta3
DG(8:0/18:2(10E,12Z)+=O(9)/0:0)
DG(8:0/18:2(10E,12Z)+=O(9)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(8:0/18:2(10E,12Z)+=O(9)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:2(10E,12Z)+=O(9)/8:0/0:0)
DG(18:2(10E,12Z)+=O(9)/8:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:2(10E,12Z)+=O(9)/8:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(8:0/0:0/18:2(10E,12Z)+=O(9))
DG(8:0/0:0/18:2(10E,12Z)+=O(9)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:2(10E,12Z)+=O(9)/0:0/8:0)
DG(18:2(10E,12Z)+=O(9)/0:0/8:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(8:0/18:2(9Z,11E)+=O(13)/0:0)
DG(8:0/18:2(9Z,11E)+=O(13)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(8:0/18:2(9Z,11E)+=O(13)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:2(9Z,11E)+=O(13)/8:0/0:0)
DG(18:2(9Z,11E)+=O(13)/8:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:2(9Z,11E)+=O(13)/8:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(8:0/0:0/18:2(9Z,11E)+=O(13))
DG(8:0/0:0/18:2(9Z,11E)+=O(13)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:2(9Z,11E)+=O(13)/0:0/8:0)
DG(18:2(9Z,11E)+=O(13)/0:0/8:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(8:0/18:3(10,12,15)-OH(9)/0:0)
DG(8:0/18:3(10,12,15)-OH(9)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(8:0/18:3(10,12,15)-OH(9)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:3(10,12,15)-OH(9)/8:0/0:0)
DG(18:3(10,12,15)-OH(9)/8:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:3(10,12,15)-OH(9)/8:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(8:0/0:0/18:3(10,12,15)-OH(9))
DG(8:0/0:0/18:3(10,12,15)-OH(9)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:3(10,12,15)-OH(9)/0:0/8:0)
DG(18:3(10,12,15)-OH(9)/0:0/8:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(8:0/18:3(9,11,15)-OH(13)/0:0)
DG(8:0/18:3(9,11,15)-OH(13)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(8:0/18:3(9,11,15)-OH(13)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:3(9,11,15)-OH(13)/8:0/0:0)
DG(18:3(9,11,15)-OH(13)/8:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:3(9,11,15)-OH(13)/8:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(8:0/0:0/18:3(9,11,15)-OH(13))
DG(8:0/0:0/18:3(9,11,15)-OH(13)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:3(9,11,15)-OH(13)/0:0/8:0)
DG(18:3(9,11,15)-OH(13)/0:0/8:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
Calcium myristate
C28H54CaO4 (494.36477940000003)
It is used as a food additive .
1-(2,6-Dihydroxyphenyl)-9-[4-hydroxy-3-(p-menth-1-en-8-yloxy)phenyl]-1-nonanone
2-O-(2-methylbutyryl)-3-O-acetyl-alpha-bisabolol-beta-D-fucopyranoside|2-O-<2-methylbutyryl>-3-O-acetyl-alpha-bisabolol-beta-D-fucopyranoside
(E)-1-acetoxy-1,4-dihydro-2-methyl-4-oxo-3-phytylnaphthalene
2-hydroxymethyl-2,3,22,23-tetrahydroxy-6,10,15,19,23-pentamethyl-6,10,14,18-tetracosatetraene
8-hydroxy-labda-13(16),14-dien-19-yl-O-acetyl-trans-coumarate
8beta-hydroxy-15-malonyloxy-18-angeloyloxy-ent-labdane
5alpha-pregn-6-ene-3beta,17alpha,20(S)-triol-3-O-beta-D-digitalopyranoside|teikagenin-3-O-beta-D-digitaloside
8beta-hydroxy-15-malonyloxy-18-senecioyloxy-ent-labdane
3beta-acetoxyglutina-5(10),6-dien-27,8alpha-olide|phyllenolide A
(4aS)-1t,9t-di-furan-3-yl-4c,6a,12c,14a-tetramethyl-(4ar,6at,7ac,12ac,14at,15at)-hexadecahydro-[1,4]dioxino[2,3-c;5,6-c]diquinolizine|6beta,7beta-epoxy-deoxynupharidine dimer
C30H42N2O4 (494.31444120000003)
3-O-methyl-6-oxopristimerol|methyl (2R,4aS,6aS,12bR,14aS,14bR)-1,2,3,4,4a,5,6,6a,8,12b,13,14,14a,14b-tetradecahydro-11-hydroxy-10-methoxy-2,4a,6a,9,12b,14a-hexamethyl-8-oxopicene-2-carboxylate
1beta,3beta,14alpha,20beta,22beta,25-hexahydroxy-5beta-ecdysteroid|aervecdysteroid C
2,3,5,22,23-pentahydroxy-2,6,10,15,19,23-hexamethyl-6,10,14,18-tetracosatetraene
(1S, 8E,12E)-1-((2S,5R)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-4,9,13,17-tetramethyl octadeca-8,12,16-triene-1,4,5-triol|sapelenin I
20(R)-25-methoxyl-dammarane-3beta,6alpha,12beta,20-tetrol
21S,23R-21,23:23,27-diepoxy-21-methoxycycloartan-1,24-diene-3,27-dione
1-(3,7-dimethylocta-2,6-dienyl)-6,6,10,10-tetramethyl-11-(2-methylpropanoyl)tetracyclo[7.3.1.13,11.03,7]tetradecane-2,12,14-trione|hypersampsone C
ethyl (22S,25R)-3alpha,12alpha,15alpha,22-tetrahydroxy-5beta-cholestan-26-oate
(2-{6-[3-(2-dimethylamino-ethyl)-indol-2-yl]-7,7,9-trimethyl-6a,7,8,10a-tetrahydro-6H-isoindolo[2,1-a]indol-11-yl}-ethyl)-methyl-amine|4-Methyl-isoborreverin|Methyl-4-Isoborreverin
(8R,9S,22R)-3-ethoxy-3-oxo-9,19-cyclo-3,4-secolanosta-4(28),6,24-trien-26-oic acid 22,26-lactone
(2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-10,13-dimethyl-17-[(2R,3R,5R)-2,3,6-trihydroxy-5,6-dimethylheptan-2-yl]-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one
(2S,3R,10R,13R,14S)-2,3,14-trihydroxy-10,13-dimethyl-17-[(2R,3R,5R)-2,3,5-trihydroxy-5,6-dimethylheptan-2-yl]-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one
(2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-10,13-dimethyl-17-[(2R,3R,5R)-2,3,6-trihydroxy-5,6-dimethylheptan-2-yl]-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one
(2S,3R,10R,13R,14S)-2,3,14-trihydroxy-10,13-dimethyl-17-[(2R,3R,5R)-2,3,5-trihydroxy-5,6-dimethylheptan-2-yl]-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one [IIN-based on: CCMSLIB00000847804]
(2S,3R,10R,13R,14S)-2,3,14-trihydroxy-10,13-dimethyl-17-[(2R,3R,5R)-2,3,5-trihydroxy-5,6-dimethylheptan-2-yl]-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one [IIN-based: Match]
His Ile Ile Ile
His Ile Ile Leu
His Ile Leu Ile
His Ile Leu Leu
His Leu Ile Ile
His Leu Ile Leu
His Leu Leu Ile
His Leu Leu Leu
Ile His Ile Ile
Ile His Ile Leu
Ile His Leu Ile
Ile His Leu Leu
Ile Ile His Ile
Ile Ile His Leu
Ile Ile Ile His
Ile Ile Leu His
Ile Leu His Ile
Ile Leu His Leu
Ile Leu Ile His
Ile Leu Leu His
Leu His Ile Ile
Leu His Ile Leu
Leu His Leu Ile
Leu His Leu Leu
Leu Ile His Ile
Leu Ile His Leu
Leu Ile Ile His
Leu Ile Leu His
Leu Leu His Ile
Leu Leu His Leu
Leu Leu Ile His
Leu Leu Leu His
(5Z,7E)-(1S,3R)-24,24-difluoro-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
C30H48F2O3 (494.3571321999999)
(5Z,7E)-(1S,3R)-18-[m-(1-hydroxy-1-methylethyl)-benzyloxy]-23,24-dinor-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
Atocalcitol
Isohomobrassinolide
Cyathsterone D
Heptaethylene glycol monododecyl ether
D019999 - Pharmaceutical Solutions > D012597 - Sclerosing Solutions D013501 - Surface-Active Agents > D011092 - Polyethylene Glycols D013501 - Surface-Active Agents > D003902 - Detergents D001697 - Biomedical and Dental Materials D002317 - Cardiovascular Agents
benzyldimethyl[3-[(1-oxoisooctadecyl)amino]propyl]ammonium chloride
tris(2-(2-Butoxyethoxy)ethyl)orthoborate
C24H51BO9 (494.36259459999997)
benzyldimethyl[3-[(1-oxooctadecyl)amino]propyl]ammonium chloride
Guanethidine sulfate
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents
Homobrassinolide
28-Homobrassinolide is a phytosteroid. 28-Homobrassinolide can be used for the research of cholesterol and glucose homeostasis[1].
trimethyl-3-[(1-oxooctadecyl)amino]propylammonium methyl sulphate
[(2R)-1-hydroxy-3-phosphonooxypropan-2-yl] docosanoate
2-[[(2R)-3-[(Z)-hexadec-9-enoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H49NO7P+ (494.32464740000006)
[(2S)-1-hydroxy-3-octanoyloxypropan-2-yl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2S)-3-hydroxy-2-octanoyloxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2R)-2-hydroxy-3-octanoyloxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2S)-2-hydroxy-3-octanoyloxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2S)-1-hydroxy-3-octanoyloxypropan-2-yl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
[(2S)-3-hydroxy-2-octanoyloxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
[(2R)-2-hydroxy-3-octanoyloxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
[(2S)-2-hydroxy-3-octanoyloxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
2-[[2-[(E)-hexadec-9-enoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H49NO7P+ (494.32464740000006)
[3-Carboxy-2-[13-(3,4-dimethyl-5-propylfuran-2-yl)tridecanoyloxy]propyl]-trimethylazanium
C29H52NO5+ (494.38452820000003)
[3-carboxy-2-[(E)-7-[5-hydroxy-2-[(1E,5Z)-3-hydroxyocta-1,5-dienyl]-3-oxocyclopentyl]hept-5-enoyl]oxypropyl]-trimethylazanium
[3-Carboxy-2-[11-(3,4-dimethyl-5-pentylfuran-2-yl)undecanoyloxy]propyl]-trimethylazanium
C29H52NO5+ (494.38452820000003)
(10E,12Z,16Z)-7-hydroxy-5,6,6,10,14,16-hexamethylspiro[2,20-dioxatricyclo[17.3.1.04,9]tricosa-4(9),5,7,10,12,16-hexaene-21,2-oxane]-3-one
2-[[3-[(E)-hexadec-9-enoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H49NO7P+ (494.32464740000006)
Guanethidine bisulfate
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents
3-(4-ethoxyphenyl)-1-[3-(4-morpholinyl)propyl]-1-[(1-propyl-3,4-dihydro-2H-quinolin-6-yl)methyl]urea
(2S,3R,10R,13R,14S)-2,3,14-Trihydroxy-10,13-dimethyl-17-[(2R,3R,5R)-2,3,5-trihydroxy-5,6-dimethylheptan-2-yl]-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one
O-[1-O-[(E)-9-Hexadecenoyl]-L-glycero-3-phospho]choline
C24H49NO7P+ (494.32464740000006)
2-[[(2R)-2-[(Z)-hexadec-9-enoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H49NO7P+ (494.32464740000006)
2-[[(2R)-3-[(Z)-heptadec-1-enoxy]-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C25H53NO6P+ (494.36103080000004)
2,3-dihydroxypropyl [2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propyl] hydrogen phosphate
[17-(5-ethyl-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
C29H50O4S (494.34296200000006)
[3-Hydroxy-2-(nonanoylamino)decyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-Hydroxy-2-(propanoylamino)hexadecyl] 2-(trimethylazaniumyl)ethyl phosphate
(2-Acetamido-3-hydroxyheptadecyl) 2-(trimethylazaniumyl)ethyl phosphate
[3-Hydroxy-2-(octanoylamino)undecyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-(Hexanoylamino)-3-hydroxytridecyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-(Butanoylamino)-3-hydroxypentadecyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-Hydroxy-2-(pentanoylamino)tetradecyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-(Heptanoylamino)-3-hydroxydodecyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-(Decanoylamino)-3-hydroxynonyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-Hydroxy-2-(undecanoylamino)octyl] 2-(trimethylazaniumyl)ethyl phosphate
(1-hydroxy-3-octanoyloxypropan-2-yl) (9Z,12Z)-nonadeca-9,12-dienoate
(1-Pentanoyloxy-3-phosphonooxypropan-2-yl) hexadecanoate
(1-Phosphonooxy-3-propanoyloxypropan-2-yl) octadecanoate
(1-Butanoyloxy-3-phosphonooxypropan-2-yl) heptadecanoate
(1-Acetyloxy-3-phosphonooxypropan-2-yl) nonadecanoate
(1-Heptanoyloxy-3-phosphonooxypropan-2-yl) tetradecanoate
(1-Hexanoyloxy-3-phosphonooxypropan-2-yl) pentadecanoate
(1-Nonanoyloxy-3-phosphonooxypropan-2-yl) dodecanoate
(1-Octanoyloxy-3-phosphonooxypropan-2-yl) tridecanoate
(1-hydroxy-3-nonanoyloxypropan-2-yl) (9Z,12Z)-octadeca-9,12-dienoate
(1-Decanoyloxy-3-phosphonooxypropan-2-yl) undecanoate
(1-hydroxy-3-undecanoyloxypropan-2-yl) (9Z,12Z)-hexadeca-9,12-dienoate
[1-hydroxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (Z)-tetradec-9-enoate
(1-decanoyloxy-3-hydroxypropan-2-yl) (9Z,12Z)-heptadeca-9,12-dienoate
[(2R)-2-decanoyloxy-3-phosphonooxypropyl] undecanoate
(1-heptanoyloxy-3-hydroxypropan-2-yl) (11Z,14Z)-icosa-11,14-dienoate
(1-hydroxy-3-propanoyloxypropan-2-yl) (13Z,16Z)-tetracosa-13,16-dienoate
(1-hexanoyloxy-3-hydroxypropan-2-yl) (11Z,14Z)-henicosa-11,14-dienoate
(1-hydroxy-3-pentanoyloxypropan-2-yl) (13Z,16Z)-docosa-13,16-dienoate
2-[[3-[(Z)-hexadec-9-enoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H49NO7P+ (494.32464740000006)
(3-hydroxy-2-undecanoyloxypropyl) (4E,7E)-hexadeca-4,7-dienoate
[1-carboxy-3-[2-hydroxy-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-1-decanoyloxy-3-phosphonooxypropan-2-yl] undecanoate
2-[[2-[(Z)-hexadec-4-enoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H49NO7P+ (494.32464740000006)
2-[[(2R)-3-[(E)-hexadec-7-enoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H49NO7P+ (494.32464740000006)
[(2S)-1-decanoyloxy-3-hydroxypropan-2-yl] (9E,12E)-heptadeca-9,12-dienoate
[(2S)-2-decanoyloxy-3-hydroxypropyl] (9E,12E)-heptadeca-9,12-dienoate
[1-carboxy-3-[2-hydroxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
2-[[2-acetyloxy-3-[(Z)-tetradec-9-enoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H49NO7P+ (494.32464740000006)
2-[[3-[(Z)-heptadec-9-enoxy]-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C25H53NO6P+ (494.36103080000004)
2-[hydroxy-[2-propanoyloxy-3-[(Z)-tridec-9-enoxy]propoxy]phosphoryl]oxyethyl-trimethylazanium
C24H49NO7P+ (494.32464740000006)
[(2R)-1-octanoyloxy-3-phosphonooxypropan-2-yl] tridecanoate
2,3,14-Trihydroxy-10,13-dimethyl-17-(2,3,6-trihydroxy-5,6-dimethylheptan-2-yl)-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one
DG(27:2)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
(3z,3as,5ar,7s,9ar,9bs)-3-[(3e,5e)-6,10-dimethyl-7-oxoundeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate
(1s,2r,4r)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl (6ar,10ar)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6ah,7h,8h,10ah-benzo[c]isochromene-2-carboxylate
1-[5-(2h-1,3-benzodioxol-5-yl)-4-pentyl-6-(piperidine-1-carbonyl)cyclohex-2-ene-1-carbonyl]piperidine
C30H42N2O4 (494.31444120000003)